Kalshi is Betting on Trial Results and FDA Decisions Now, What's Next?
FDA Announces 3 Final Guidances to Increase Patient Participation in Oncology Trials
Evis Sala Announces a Landmark Oncology Partnership Between Albania and Italy
First Chemotherapy Session: What to Expect
RxPONDER Analysis: Ovarian Reserve May Refine Chemotherapy Decisions in HR-Positive Breast Cancer
Wafik El-Deiry: Scientific Freedom and Diverse Thinking Drive Better Medicine
SABCS 2026 Male Breast Cancer Advocate Scholarship
Herbert Loong: Prospective Open-labelled Phase 2 Pembrolizumab in Acral Lentiginous Melanoma
Enter the Recurrence Score and clinical context to view the RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
